Publications & Media

The latest news in technology and science from Protagenic

Protagenic Papers


Upcoming Webinars

Protagenic Therapeutics, Inc. (PTIX) Virtual Science Review


Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders will host a Scientific review of its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction. The review will take place on Wednesday, September 8th from 10:00-11:00 AM ET.

The webinar will feature presentations by scientific founder David Lovejoy, PhD; PTI Chief Operating Officer Andrew Slee, PhD; and its Chief Medical Officer Robert Stein, MD, PhD.

  • Dr.David Lovejoy, PhD will present events leading to the discovery of PT00114 and its subsequent evolution.
  • Chief Operating Officer Andrew Slee, PhD will present the compelling evidence which has been generated in all relevant disease models.
  • Chief Medical Officer Robert Stein, MD, PhD will discuss how PT00114 may fit in the pharmacopeia of available therapies for stress-related disorders as well as the unmet need of addiction withdrawal therapy.


In addition, the company will provide an update on PT00114’s upcoming clinical program, including the structure of the anticipated Phase I/IIa multi-center clinical trial. The trial’s Principal Investigator will be Dr. Maurizio Fava, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital.

The session will be followed by Q&A.


or contact James Carbonara at Hayden IR, Office:(646)-755-7412, or email

Past Webinars

Protagenic Therapeutics, Inc. (PTIX) Key Opinion Leader (KOL) PT00114 Webinar

Protagenic Therapeutics, Inc.’s key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction.

The webinar features a presentation by KOL Dr. Maurizio Fava, Massachusetts General Hospital (MGH), who is serving as principal investigator in Protagenic’s upcoming Phase 1/2a clinical trial.

Protagenic’s management team also provided an overview of the ongoing clinical development program and potential commercial opportunity for PT00114, which is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain.


August 2021

PTI Corporate Overview Slide Deck

Breakthrough Therapeutics for Stress-Related Neuropsychiatric Disorders

June 17, 2021

The HCWainwright Psychedelics Conference PTIX Presentation

Psychedelics in Psychiatry and Beyond

© 2021 Protagenic Therapeutics, Inc.